ClinicalTrials.gg
Not yet recruitingNCT07252544Updated Nov 26, 2025

Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)

A Phase 3 interventional study of Isosorbide Mononitrate and Butylphthalide in Stroke, Lacunar, Stroke, Acute Ischemic and Cerebral Small Vessel Diseases, sponsored by Beijing Tiantan Hospital. Not yet recruiting. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Beijing Tiantan Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,156
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Study summary

The goal of this multicenter, double-blind, 2×2 factorial randomized controlled trial is to evaluate the efficacy and safety of isosorbide mononitrate, butylphthalide, and their combination in reducing disability in patients with acute lacunar stroke.

Read the detailed description

There is an urgent need for effective therapeutic strategies for acute ischemic cerebral small vessel disease (CSVD). Isosorbide mononitrate and butylphthalide may exert protective effects; however, large-scale randomized controlled trials are required to confirm their efficacy and safety and to guide clinical practice.

In this study, patients presenting with a clinical lacunar syndrome within 7 days of onset will be randomly assigned, in a 1:1:1:1 ratio, to one of four groups in addition to routine care: (1) isosorbide mononitrate plus butylphthalide, (2) isosorbide mononitrate plus butylphthalide placebo, (3) isosorbide mononitrate placebo plus butylphthalide, or (4) isosorbide mononitrate placebo plus butylphthalide placebo. The treatment period will last 6 months, with a total follow-up of 1 year, including assessments at 7 days, 1 month, 3 months, 6 months, and 1 year.

The primary efficacy outcome is post-stroke disability at 6 months. The primary safety outcome is moderate or more severe headache within 6 months.

02

Conditions studied

  • Stroke, Lacunar
  • Stroke, Acute Ischemic
  • Cerebral Small Vessel Diseases
03

In context

Stroke, Lacunar

21 studies on the registry are indexed under Stroke, Lacunar; 9 are open to participants now.

This study's planned enrollment of 3,156 is above the median of 60 across 15 interventional studies indexed under Stroke, Lacunar.

Browse Stroke, Lacunar studies →

Lead sponsor

Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 30 years;
  2. Clinical lacunar syndrome within 7 days;
  3. Brain CT/MRI after symptom onset:

    1. a relevant (in time and location) acute lacunar infarct;
    2. if no relevant lesion, symptom duration >24 hours, with no other suspected stroke etiologies (such as cerebral hemorrhage, cortical infarction, seizures, etc.)
  4. score meeting the following criteria:

    1. MoCA ≥ 13 if educated ≤ 6 years;
    2. MoCA ≥ 15 if 7 ≤ educated ≤ 12 years;
    3. MoCA ≥ 18 if educated ≥ 13 years;
  5. mRS ≤ 1 prior to this episode;
  6. Patient or a legally authorized representative signed .

Exclusion criteria

Exclusion Criteria:

  1. Ischemic stroke of large artery atherosclerosis, cardioembolism, or other etiologies (TOAST classification);
  2. Diagnosed or suspected hereditary CSVD;
  3. Intracerebral hemorrhage within the past 3 months including parenchymal, intraventricular, subarachnoid hemorrhage, subdural/epidural hematoma;
  4. Neurodegenerative diseases or systemic diseases that may lead to cognitive impairment, such as Alzheimer's disease, mixed dementia, Parkinson's disease, systemic diseases, hepatic encephalopathy, or uremic encephalopathy.
  5. Previously diagnosed psychiatric disorders ( criteria).
  6. Other active neurological disorders (e.g., recurrent seizures, brain tumors, vascular malformations, untreated aneurysms >3 mm).
  7. Hypotension (seated systolic blood pressure \<100 mmHg), bradycardia (heart rate \<60 bpm), sick sinus syndrome or severe cardiopulmonary disease.
  8. History of congestive heart failure, acute myocardial infarction or other severe cardiac dysfunctions ( Class III-IV).
  9. Coagulation disorders, bleeding tendency or systemic bleeding, including but not limited to >3× (ULN), count \<50×109/L, hemophilia, capillary fragility, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, or vitreous hemorrhage, etc.
  10. Severe hepatic or renal insufficiency (note: severe hepatic insufficiency is defined as or AST > 3×ULN or acute hepatitis, chronic active hepatitis, cirrhosis; severe renal insufficiency is defined as \< 45 ml/min/1.73m², \< 40 ml/min, or known chronic kidney disease of stage 3 or higher).
  11. Head trauma, intracranial or spinal surgery, major surgical procedures or severe trauma within the past 4 weeks.
  12. ISMN or NBP use within the past 3 days.
  13. Have to ISMN or NBP, or allergy to their components.
  14. Have to use the contraindicated drugs of this trial for a long time.
  15. Pregnant, breastfeeding or planning to pregnant during this study.
  16. Unable to tolerate MRI or with MRI contraindications.
  17. Have severe diseases or expected survival \<12 months.
  18. Participate in other clinical trials within 30 days before this trial.
  19. Unlikely to comply with study procedures and follow-up procedures for whatever reason in the opinion of the research physician.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,156 participants (estimated)

Study arms

  • Experimental
    isosorbide mononitrate plus butylphthalide

    Drug: Isosorbide Mononitrate · Drug: Butylphthalide

  • Experimental
    isosorbide mononitrate plus butylphthalide placebo

    Drug: Isosorbide Mononitrate · Drug: Butylphthalide Placebo

  • Experimental
    isosorbide mononitrate placebo plus butylphthalide

    Drug: Butylphthalide · Drug: Isosorbide Mononitrate Placebo

  • Placebo comparator
    isosorbide mononitrate placebo plus butylphthalide placebo

    Drug: Isosorbide Mononitrate Placebo · Drug: Butylphthalide Placebo

Interventions

  • Days 1-7: Isosorbide mononitrate injection, 20 mg once daily by intravenous infusion. Days 8-6 months: Isosorbide mononitrate sustained-release tablets, 40 mg once daily orally (dose reduced to 20 mg once daily during the final week).

  • Days 1-7: Butylphthalide injection, 25 mg twice daily by intravenous infusion. Days 8-6 months: Butylphthalide soft capsules, 200 mg three times daily orally.

  • DrugIsosorbide Mononitrate Placebo

    Days 1-7: Isosorbide mononitrate injection placebo, once daily by intravenous infusion. Days 8-6 months: Isosorbide mononitrate sustained-release tablet placebo, once daily orally (dose reduced to half a tablet once daily during the final week).

  • DrugButylphthalide Placebo

    Days 1-7: Butylphthalide injection placebo, twice daily by intravenous infusion. Days 8-6 months: Butylphthalide soft capsule placebo, 2 capsules three times daily orally.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with post-stroke disability at 6 months

    A composite endpoint defined as the occurrence of any of the following: modified Rankin Scale (mRS) score ≥ 3, major adverse cardiovascular events (MACE), cognitive impairment, or all-cause mortality. The mRS measures post-stroke functional outcome on a scale from 0 (no symptoms) to 6 (death). MACE includes non-fatal stroke, non-fatal myocardial infarction (MI), and vascular death.The assessment of cognitive function involves three stages: a cognitive screening test, supplementary cognitive testing, and adjudication by an expert panel. The Beijing version of the Montreal Cognitive Assessment (MoCA) is used as the cognitive screening scale. Scores on the MoCA range from 0 to 30, with lower scores indicating greater cognitive impairment.The supplementary cognitive assessment includes the evaluation of several domains: executive function, attention and processing speed, language, and memory, as well as activities of daily living.

    Time frame: 6 months

  2. Incidence of moderate or more severe headache within 6 months

    Headache severity is assessed using the Numerical Rating Scale (NRS), where: 0 indicates no pain; 1 represents a mild headache (including feelings of head pressure or throbbing that are not considered painful); a score of 4 or higher (≥4) represents a headache of at least moderate intensity; and 10 represents the worst headache imaginable to the subject.

    Time frame: 6 months

Secondary outcomes

  1. Proportion of participants with post-stroke disability at 1 year

    The difinition of post-stroke disability is the same as the primary outcome measure.

    Time frame: 1 year

  2. Proportion of participants with the modified Rankin Scale (mRS) score ≥ 3 at 6 months and 1 year

    The modified Rankin Scale (mRS) is used to measure the degree of disability and dependence after a stroke. The scale ranges from 0 to 6. A score of 0 represents no symptoms, 1 represents no significant disability, 2 represents slight disability, 3 represents moderate disability, 4 represents moderately severe disability, 5 represents severe disability, and 6 represents death.

    Time frame: 6 months and 1 year

  3. Incidence of recurrent stroke within 6 months and 1 year

    Time frame: 6 months and 1 year

  4. Proportion of participants with dementia at 6 months and 1 year

    Dementia (all of the following criteria must be met): A. Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition) based on:1.Concern from the individual, a knowledgeable informant, or the clinician that there has been a significant decline in cognitive function. 2.A substantial impairment in cognitive performance, preferably documented by standardized neuropsychological testing or, in its absence, another quantified clinical assessment. B. The cognitive deficits interfere with independence in everyday activities (i.e., at a minimum, requiring assistance with complex instrumental activities of daily living, such as paying bills or managing medications). C. The cognitive deficits do not occur exclusively in the context of a delirium. D. The cognitive deficits are not better explained by another mental disorder.

    Time frame: 6 months and 1 year

  5. National Institutes of Health Stroke Scale (NIHSS) scores at 7 days, 6 months, and 1 year (including changes from baseline)

    The National Institutes of Health Stroke Scale (NIHSS) is a standardized tool used to objectively measure the severity of a stroke by quantifying a patient's neurological deficits. Its primary purposes are to evaluate the acuity of a stroke, guide treatment decisions, and predict patient outcomes. The scale's total score ranges from 0 to 42, with higher scores representing more severe neurological impairment.

    Time frame: baseline, 7 days, 6 months, and 1 year

  6. Incidence of hypotension within 6 months

    Hypotension is defined as a systolic blood pressure (SBP) of less than 100 mmHg or a 30% decrease from baseline.

    Time frame: 6 months

  7. Incidence of syncope within 6 months

    Syncope is a transient loss of consciousness caused by transient global cerebral hypoperfusion, characterized by a rapid onset, short duration, and spontaneous, complete recovery. The diagnosis requires the following conditions to be met: 1. A transient loss of consciousness with a rapid onset (from a few seconds to 1 minute); 2. A short duration (from a few seconds to a few minutes); 3. Spontaneous and complete recovery; 4. Absence of focal neurological signs; 5. Exclusion of head trauma and epileptic seizures.

    Time frame: 6 months

  8. Incidence of liver function impairment within 6 months

    Liver function impairment may be diagnosed if at least one of the following criteria is met: 1. Serum AST or ALT \> 5 × the upper limit of normal (ULN), or ALP \> 2 × ULN (or from an abnormal baseline value); 2. Serum total bilirubin (TBil) \> 2.5 mg/dL (42.75 μmol/L) accompanied by any elevation in serum AST, ALT, or ALP levels.

    Time frame: 6 months

  9. Incidence of any bleeding within 6 months

    Bleeding events are evaluated using the GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) classification and categorized as severe, moderate, or mild.

    Time frame: 6 months

  10. Incidence of symptomatic intracranial hemorrhage within 6 months

    According to the Heidelberg Bleeding Classification established at the 12th Thrombolytic Therapy in Acute Ischemic Stroke workshop in Germany in 2015, symptomatic intracerebral hemorrhage (sICH) is defined as meeting all of the following conditions: 1. Any form of intracranial hemorrhage (including types 1a, 1b, 1c, 2, 3a, 3b, 3c, and 3d of the Heidelberg classification) that is detected by imaging (head CT or MRI) and confirmed by a radiologist; 2. The patient experiences clinical deterioration, defined as: an increase in the NIHSS score of ≥ 4 points from the last score prior to deterioration, OR an increase of ≥ 2 points on any single item of the NIHSS, OR an outcome leading to tracheal intubation, decompressive craniectomy, ventricular drainage, or other major medical/surgical intervention; 3. The clinical deterioration cannot be explained by any cause other than the intracranial hemorrhage.

    Time frame: 6 months

Other outcomes

  1. ≥ 80% of patients taking ≥ 50% of the trial dose up to 6 months

    Time frame: 6 months

  2. Concentration of blood biomarkers predictive of drug efficacy at 6 months and 1 year

    Changes in the levels of neuroinflammation indicators, thormbotic inflammation indicators and novel blood-based biomarkers \[e.g. phosphodiesterase 3A(PDE3A), transgelin 2(TAGLN2), integrin subunit alpha M(ITGAM), protein phosphatase, Mg2+/Mn2+ dependent 1D(PPM1D)\] associated with the prognosis of CSVD compared with baseline levels at 6 months and 1 year.

    Time frame: baseline, 6 months and 1 year

  3. Changes in white matter integrity at 6 months and 1 year

    Assessed using Diffusion Tensor Imaging (DTI) with fiber tractography to evaluate the structural integrity of white matter fibre tract.

    Time frame: baseline, 6 months and 1 year

  4. Changes in functional connectivity networks at 6 months and 1 year

    Assessed using resting-state functional MRI (rs-fMRI) to measure the temporal correlation and connectivity between brain regions within a specific network.

    Time frame: baseline, 6 months and 1 year

  5. Changes in neurovascular coupling (imaging biomarker) at 6 months and 1 year

    Assessed by combining Arterial Spin Labeling (ASL) and Blood-Oxygen-Level-Dependent (BOLD) fMRI to measure the hemodynamic response following neural activity in specific regions.

    Time frame: baseline, 6 months and 1 year

  6. Changes in glymphatic function at 6 months and 1 year

    Assessed using two complementary methods: the Diffusion Tensor Image Analysis Along the Perivascular Space (DTI-ALPS) index, which serves as an imaging proxy for glymphatic system activity, and the quantification of Basal Ganglia Enlarged Perivascular Spaces (BG-EPVS) volume from high-resolution 3D T2-weighted images.

    Time frame: baseline, 6 months and 1 year

  7. Changes in brain tissue free water at 6 months and 1 year

    Assessed using multi-compartment Diffusion Tensor Imaging (DTI) models to quantify the fraction of extracellular free water, considered a marker for neuroinflammation and edema.

    Time frame: baseline, 6 months and 1 year

  8. Changes in heart rate variability (HRV) at 6 months and 1 year

    Assessed via analysis of Electrocardiogram (ECG) recordings to evaluate the balance of the autonomic nervous system.

    Time frame: baseline, 6 months and 1 year

  9. Changes in orthostatic blood pressure at 6 months and 1 year

    Assessed via orthostatic testing to measure the cardiovascular system's response to postural changes.

    Time frame: baseline, 6 months and 1 year

  10. Changes in cerebral autoregulation at 6 months and 1 year

    Assessed using Transcranial Doppler (TCD) ultrasonography to measure the brain's ability to maintain stable cerebral blood flow despite changes in blood pressure.

    Time frame: baseline, 6 months and 1 year

  11. Changes in cerebrovascular reactivity at 6 months and 1 year

    Assessed using Transcranial Doppler (TCD) ultrasonography to measure the dilatory capacity of cerebral blood vessels in response to a vasodilatory stimulus (e.g., CO₂).

    Time frame: baseline, 6 months and 1 year

  12. Changes in neurovascular coupling (cerebral hemodynamics parameter) at 6 months and 1 year

    Assessed using task-state Transcranial Doppler (TCD) ultrasonography to measure the relationship between transient neural activity and the subsequent cerebral blood flow response.

    Time frame: baseline, 6 months and 1 year

  13. Changes in electroencephalography (EEG) oscillatory dispersion at 6 months and 1 year

    Assessment of neuroelectrical signals by quantifying the dispersion and variability of oscillatory activity within different EEG frequency bands (e.g., Delta, Theta, Alpha, Beta).

    Time frame: baseline, 6 months and 1 year

  14. Changes in rey auditory verbal learning test (RAVLT) score at 6 months and 1 year

    Assessed using the Rey Auditory Verbal Learning Test (RAVLT) to measure memory and learning ability. Performance is scored by the number of words correctly recalled, with scores for a single trial ranging from a minimum of 0 to a maximum of 15. A higher score indicates better performance.

    Time frame: baseline, 6 months and 1 year

  15. Changes in color trails test (CTT) score at 6 months and 1 year

    Assessed using the Color Trails Test (CTT) to measure sustained attention and processing speed. Performance is scored by the time required to complete the task. While the theoretical minimum is greater than 0 seconds, the test is typically discontinued if not completed within a maximum cutoff time of 240 seconds. A lower score (faster time) indicates better performance.

    Time frame: baseline, 6 months and 1 year

  16. Changes in Stroop color and word test (SCWT) score at 6 months and 1 year

    Assessed using the Stroop Color and Word Test (SCWT) to measure executive function. Performance is scored by the time to completion and the number of errors. The minimum score is 0 seconds and 0 errors. There is no theoretical maximum time, but the maximum number of errors is limited by the total number of items on the test card (e.g., 100 errors on a 100-item card). Lower times and fewer errors indicate better performance.

    Time frame: baseline, 6 months and 1 year

  17. Changes in verbal fluency test (VFT) score at 6 months and 1 year

    Assessed using the Verbal Fluency Test (VFT) to measure language production and executive control. Performance is scored by the total number of correct words generated in a set time. The minimum score is 0, but there is no defined maximum score. A higher score indicates better performance.

    Time frame: baseline, 6 months and 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Aug 2027, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Nov 26, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Aug 31, 2027
CompletionEst.
Feb 29, 2028
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07252544
Collaborators
Shenzhen Second People's Hospital
Responsible party
yilong Wang (Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Nov 26, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Nov 26, 2025

Study contacts

Ying Gao
Contact
tjssgaoying@163.com
+86 10 59976165
Yao Lu
Contact
luyao970131@163.com
+86 10 59976254
Yilong Wang
principal investigator · Beiling Tiantan Hospital, Capital Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Isosorbide mononitrate · Butylphthalide

Start the discussion